AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancerBRAVE, Sandra R; ODEDRA, Rajesh; WAINWRIGHT, Anna et al.International journal of oncology. 2011, Vol 39, Num 1, pp 271-278, issn 1019-6439, 8 p.Article

A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopinCOSULICH, Sabina C; JAMES, Neil H; NEEDHAM, Maurice R. C et al.Carcinogenesis (New York. Print). 2000, Vol 21, Num 9, pp 1757-1760, issn 0143-3334Article

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid CancersSMITH, Neil R; BAKER, Dawn; JÜRGENSMEIER, Juliane M et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3548-3561, issn 1078-0432, 14 p.Article